VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2022 | Bladder cancer at ASCO 2022: RC48 vedotin, chemoimmunotherapy

Jonathan E. Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses updates in the management of urothelial management presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, including the use of RC48 vedotin, a novel antibody-drug conjugate as well combination approaches with immune checkpoint inhibitors and chemotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter